European Pharmaceutical Review

APRIL 21, 2023

In addition, the number of active substances detected in the environment has been increasing with unknown consequences for ecosystems and the accumulation of substances in food chains. Giving environmental risk assessments teeth Since 2005, the authorisation of a human pharmaceutical product requires an environmental risk assessment (ERA).

Pharma 98

Pharma Food and Drug Administration Medicine Pharmaceutical 98

European Pharmaceutical Review

OCTOBER 19, 2022

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.

Food and Drug Administration 96

Food and Drug Administration Pharmaceutical products Pharmaceutical FDA 96

European Pharmaceutical Review

APRIL 8, 2025

They should remain informed, knowledgeable of the PAT, monitor compliance regularly, especially if PAT is directly involved in drug substance production and the instruments are product-contact and in the regulatory filing dossier. Q8(R2) Pharmaceutical Development. International Council for Harmonisation (ICH), 2005.

Manufacturing 52

Manufacturing Food and Drug Administration Management Pharmaceutical 52